Summary
Other Scenarios:
- PFE - GSK
- PFE - SNY
- GSK - PHRM
- SNY - PHRM
| Buyer: | Pfizer Inc. (PFE) | Last Price: | 21.35 | Market Cap.: | 144.35B |
|---|---|---|---|---|---|
| Target: | Pharmion Corporation (PHRM) | Last Price: | 72.32 | Market Cap.: | 2.71B |
Lines of Business Summary:
- Pfizer Inc. (PFE) competes in 2 industries and 252 product/service groups
- Pharmion Corporation (PHRM) competes in 1 industry and 7 product/service groups
- A combined entity will have 1% Product/Service Group overlap
- Pfizer Inc. (PFE) has 17 and Pharmion Corporation (PHRM) has 1 suppliers that rely on a material % of their business. They share 0 in common.
- Pfizer Inc. (PFE) has 3 and Pharmion Corporation (PHRM) has 3 customers that derive significant revenue from each. They share 2 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
918 |
Biopharmaceuticals |
|
|
375 |
|
Medical Devices |
|
254 | |
|
Nutritional Health |
|
27 | |
|
Outsourced Services |
|
66 | |
|
Veterinary Products and Services |
|
7 | |
|
Technology |
|
1,036 | |
|
Software |
|
312 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 240)
|
Target (Total: 5)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 84)
|
Target (Total: 6)
|
Buyer (Total: 14)
|
Target (Total: 4)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 86,600 | 513 |
| Revenue Per Employee | 596,090.4 | 558,770.6 |
| Total Revenue | 12,870.0 | 71.5 |
| Total Expenses | 9,900.0 | 102.6 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
2,625.0 | 19.7 |
|
SG&A Expense
|
4,653.0 | 50.0 |
|
Research & Development
|
2,260.0 | 30.4 |
|
Other Operating Expense
|
-610.0 | 0.0 |
|
Operating Income
|
2,970.0 | -31.2 |
|
Unusual Income
|
216.0 | 0.0 |
|
LT Debt to Capital
|
10.11 | 0 |
|
Fwd P/E
|
9.11 | -395.28 |
|
Fwd P/Rev
|
3.03 | 7.21 |
| Book Value | 64,917.0 | 358.9 |
|
Curr Portion of LTD/Cap Lease
|
1,024.0 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals > Oncology
Business Description
Buyer
Pfizer Inc. (Pfizer) is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. The Company also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. In January 2008, the Company completed the acquisition of Coley Pharmaceutical Group, Inc., a company whose area of capability is immunotherapy with emphasis on Toll-like receptor research and development. In January 2008, it completed the acquisition of CovX Research LLC, which is a biotherapeutics company focused on preclinical oncology and metabolic research and a developer of a technology platform.
Target
Pharmion Corporation is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. The Company has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram (Thalidomide Pharmion), a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma. In January 2008, Celgene Corporation has cleared its pending acquisition of Pharmion.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
76.79 | 72.66 |
|
Operating Margin %
|
19.16 | -25.91 |
|
Quick Ratio
|
1.65 | 3.64 |
|
Current Ratio
|
2.15 | 4 |
|
Coverage Ratio
|
0 | -0.15 |
| Total Assets | 115,268.0 | 443.3 |
| Return on Equity % | 12.7 | -17.79 |
| Return on Assets % | 7.16 | -14.4 |
|
Cash+ ST Inv. Per Share
|
3.84 | 6.67 |
| Total Debt | 13,139.0 | 0.0 |
| Total Debt to Equity % | 20.21 | 0 |
| Total Debt to Tangible Equity % | 56.81 | 0 |
|
Debt to Asset %
|
11.40 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Technology |
|
|
|
Software |
|
|
|
Industry-Specific
Software that has functionality specific to a vertical industry.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the risk of chest pains by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Agonists
Therapeutics that treat abnormal rhythm of the heart by increasing the entry of sodium ions into the heart muscle to extending the time an electrical impulse travels across a neuron.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that assist the primary treatment of the ineffective pumping of the heart by dilating blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Selective Aldosterone Receptor Antagonists (SARA)
Therapeutics that selectively block the action of aldosterone, a chemical implicated in causing cardiovascular disease.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the ineffective pumping of the heart by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Adjunctive Treatment |
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat irreversible damage to the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Buyer Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting stimulation of alpha adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Selective Aldosterone Receptor Antagonists (SARA)
Therapeutics that selectively block the action of aldosterone, a chemical implicated in causing hypertension.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that prevent strokes by by blocking the influx of calcium ions into vascular cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat damage to nerve cells of the brain by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Nausea/Vomiting |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Familial Adenomatous Polyposis (FAP) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat colon polyps by inducing suicide in the abnormal cells.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that prevent edema by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Adrenal Gland Disorders |
|
|
|
Primary Aldosteronism |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat aldosteronism by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Alpha-Glucosidase Inhibitors
Therapeutics that treat diabetes by stopping the enzyme that releases glucose from larger molecules.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Cortisols
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Buyer Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Growth Hormone Receptor Antagonists
Therapeutics that treat acromegaly by binding to and thus blocking growth hormone receptors. This results in decreased secretion of growth hormone as well as IGF-1, which is responsible for the debilitating effects of the disease.
Buyer Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Buyer Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Turner`s Syndrome |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Female |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Myelodysplastic Syndromes (MDS) |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat pain associated with chronic inflammation of the joints, without upsetting the stomach with a non-steroidal compound and an anti-ulcer agent.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Glycopeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Glycopeptides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Ocular Infections |
|
|
|
Tetracyclines/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting protein synthesis and damaging the cell membrane.
Buyer Products:
|
|
|
|
Tetracyclines/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting protein synthesis, damaging the cell membrane and suppressing the full immune response.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumonia |
|
|
|
Polypeptides
Therapeutics that treat bacterial infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Systemic |
|
|
|
Mycobacterium Avium Complex (MAC) Disease |
|
|
|
Antitubercular Agents
Therapeutics that treat infection caused Mycobacterium avium in soil that spreads to a variety of organs and tissues by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Gonorrhea |
|
|
|
Penicillin Derivatives
Therapeutics that treat a common sexually transmitted disease caused by gonococcus bacterium by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Vaginitis |
|
|
|
Lincosamides
Therapeutics that treat inflammation of the mucous membrane of the vagina caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Echinocandins
Therapeutics that treat fungal infections by inhibiting the synthesis of a major cell wall component.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Echinocandins
Therapeutics that treat fungal infections due to candidiasis through a broad spectrum fungicidal action.
Buyer Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Aminoquinolines/Macrolides
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth and inhibiting RNA-dependent protein synthesis.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) |
|
|
|
Fibromyalgia Syndrome (FMS) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Fibromyalgia Syndrome by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat inflammation by inhibiting the action of prostaglandins while simultaneously protecting the stomach from the pain killing medication.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat pain associated with chronic inflammation of the joints, without upsetting the stomach with a non-steroidal compound and an anti-ulcer agent.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Buyer Products:
|
|
|
|
Dementia |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat dementia by preventing the breakdown of a the neurotransmitter, acetylcholine.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Buyer Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Motion Sickness |
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat anxiety by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Serotonin/Dopamine Receptor Blocking Agents |
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Serotonin/Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Hemorrhage |
|
|
|
Prostaglandins
Therapeutics that treat hemorrhage by acting as vasoconstrictors, thus reducing blood flow.
Buyer Products:
|
|
|
|
Induction/Cervical Ripening |
|
|
|
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.
Buyer Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
|
Termination (Abortion) |
|
|
|
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.
Buyer Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Progestins
Therapeutics that treat endometriosis pain by increasing progesterone level in the body.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
These therapeutics are male sex hormones.
Buyer Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat disorders characterized by thinning of the vaginal walls blocking estrogen receptors.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat breast cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Cardioprotective Agents
Therapeutics that help reduce damage to the heart caused by treatments for breast cancer by interfering with free radical generation which results in cardiomyopathy.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Malignant Melanoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat melanoma by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat gastric cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Endocrinology |
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)
Therapeutics that treat and manage tumors of the thyroid gland by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Neuroblastoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Toll-Like Receptor Agonists
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by stimulating the immune system.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by inhibit a specific enzyme needed for the replication and transcription of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat lung cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Urology |
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat kidney cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Estrogens
Therapeutics that treat and manage primary tumors of the prostate gland by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Antagonists
Therapeutics that treat and manage primary tumors of the prostate gland by blocking the action of gonadotropin releasing hormone and thus decreasing levels of testosterone.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Transitional Cell Carcinoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Glaucoma |
|
|
|
Prostanoid Selective FP Receptor Agonists
Therapeutics that increase the outflow of fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Tetracyclines/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat irritation and inflammation of the eye by inhibiting the growth of bacteria and by preventing the accumulation of inflammatory cells.
Buyer Products:
|
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Buyer Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Prostanoid Selective FP Receptor Agonists
Therapeutics that treat a condition characterized by increased pressure in the fluid of the eye by increasing the outflow of fluid of the eye.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that result in anesthesia by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Prophylactic Treatments |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
Target Products:
|
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
Therapeutics that treat puberty disorders by providing male sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat the inability to control urinary excretory functions by blocking the action of choline and other cholinergic agents by binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine without striping the body of potassium.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Cannabinoid Receptor Antagonists
Therapeutics that suppress appetite by blocking endogenous cannabinoid binding to neuronal CB1 receptors.
Buyer Products:
|
|
|
|
Prader-Willi Syndrome |
|
|
|
Growth Hormones
Therapeutics that treat a rare genetic disorder with a number of symptoms, the most significant of which is obesity, by supplying the body with growth hormones.
Buyer Products:
|
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Home Testing |
|
|
|
Urine |
|
|
|
Pregnancy
Home pregnancy testing kits.
Buyer Products:
|
|
|
|
Immunoassays |
|
|
|
Analyzers |
|
|
|
Allergy
Analyzers used to perform allergy testing.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Men`s Health
Products consisting of dietary/naturopathic supplements that are intended to support men's health.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Technology |
|
|
|
Software |
|
|
|
Industry-Specific |
|
|
|
Healthcare/Pharma |
|
|
|
Business Management/Information Systems |
|
|
|
Operations Support |
|
|
|
Customer Relationship Management |
|
|
|
Patient-Provider Communications
Software designed to facilitate communications between multiple healthcare providers and their patients for the purpose of providing education and improving patient well-being.
Buyer Products:
|
|
|
|
Patient Data Management |
|
|
|
Capture
Software that automates the capture of patient data from a paper-based patient record.
Buyer Products:
|
|
|
|
Patient Records
Software involved in the management of patient records, including Electronic Medical Records, Master Patient Index, Physical Record Tracking, and the automation of these processes.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 115,986.006 | 11.18 | 10.85 | 2.57 | 2.53 | 15.20 | |
|
sanofi-aventis (ADR)
|
|
n/a | 98,531.811 | 16.69 | 9.14 | 2.25 | 2.40 | n/a | |
|
Genentech, Inc.
|
|
n/a | 83,607.511 | 30.19 | 25.16 | 7.13 | 6.43 | 9.13 | |
|
Celgene Corporation
|
|
n/a | 22,917.366 | 101.21 | 38.96 | 16.30 | 11.48 | 8.45 | |
|
SuperGen, Inc.
|
|
n/a | 135.648 | 10.37 | -12.63 | 5.91 | 3.71 | 1.48 | |
|
Poniard Pharmaceuticals, Inc.
|
|
n/a | 132.393 | 0.00 | -3.07 | n/a | 12.14 | 1.53 | |
|
Vion Pharmaceuticals, Inc.
|
|
n/a | 25.897 | 0.00 | -0.71 | 1,194.74 | n/a | 3.14 | |
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 162,161.754 | 18.24 | 19.03 | 3.86 | 3.93 | 5.53 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 115,986.006 | 11.18 | 10.85 | 2.57 | 2.53 | 15.20 | |
|
Novartis AG (ADR)
|
|
n/a | 108,444.656 | 9.08 | 13.48 | 2.78 | 2.71 | 3.88 | |
|
sanofi-aventis (ADR)
|
|
n/a | 98,531.811 | 16.69 | 9.14 | 2.25 | 2.40 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 90,400.858 | 27.60 | 12.73 | 3.74 | 3.70 | 5.64 | |
|
Genentech, Inc.
|
|
n/a | 83,607.511 | 30.19 | 25.16 | 7.13 | 6.43 | 9.13 | |
|
Wyeth
|
|
n/a | 55,284.879 | 11.98 | 12.11 | 2.47 | 2.48 | 4.04 | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 144,347.120 | 17.73 | 9.11 | 2.98 | 3.03 | 6.24 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 115,986.006 | 11.18 | 10.85 | 2.57 | 2.53 | 15.20 | |
|
sanofi-aventis (ADR)
|
|
n/a | 98,531.811 | 16.69 | 9.14 | 2.25 | 2.40 | n/a | |
|
Genentech, Inc.
|
|
n/a | 83,607.511 | 30.19 | 25.16 | 7.13 | 6.43 | 9.13 | |
|
Eli Lilly & Co.
|
|
n/a | 56,508.154 | 19.14 | 12.64 | 3.03 | 2.79 | 5.04 | |
|
Celgene Corporation
|
|
n/a | 22,917.366 | 101.21 | 38.96 | 16.30 | 11.48 | 8.45 | |
|
Eisai Co., Ltd (ADR)
|
|
n/a | 9,661.528 | 13.56 | 13.89 | 1.46 | 1.40 | 2.29 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 4,249.041 | 284.76 | 58.61 | 8.05 | 7.65 | 5.90 | |
|
SuperGen, Inc.
|
|
n/a | 135.648 | 10.37 | -12.63 | 5.91 | 3.71 | 1.48 | |
|
Poniard Pharmaceuticals, Inc.
|
|
n/a | 132.393 | 0.00 | -3.07 | n/a | 12.14 | 1.53 | |
|
Vion Pharmaceuticals, Inc.
|
|
n/a | 25.897 | 0.00 | -0.71 | 1,194.74 | n/a | 3.14 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Renovis, Inc.
|
|
96.90% | 73.533 | 0.00 | -3.13 | 6.94 | 6.56 | 0.91 | |
|
Neurocrine Biosciences, Inc.
|
|
90.90% | 192.135 | 0.00 | -2.40 | 156.82 | 14.78 | 1.62 | |
|
Nektar Therapeutics
|
|
64.00% | 578.863 | 0.00 | -7.11 | 2.12 | 6.83 | 4.34 | |
|
VirtualScopics, Inc.
|
|
35.20% | 17.113 | 0.00 | n/a | 3.19 | n/a | 4.42 | |
|
Rigel Pharmaceuticals, Inc.
|
|
29.90% | 633.916 | 0.00 | -7.91 | 50.31 | 53.66 | 7.81 | |
|
Medarex, Inc.
|
|
21.00% | 1,097.420 | 0.00 | -5.92 | 19.50 | 21.35 | 2.46 | |
|
Helios & Matheson North America Inc
|
|
21.00% | 5.536 | 0.00 | -9.24 | 0.27 | 0.26 | 1.03 | |
|
Monogram Biosciences, Inc.
|
|
19.00% | 166.160 | 0.00 | -8.86 | 3.84 | 2.60 | n/a | |
|
Pharsight Corporation
|
|
17.00% | 44.598 | 0.00 | 29.56 | 1.59 | 1.58 | 5.07 | |
|
WuXi PharmaTech (Cayman) Inc. (ADR)
|
|
15.40% | 1,230.567 | 47.81 | 50.81 | 10.17 | 10.07 | 5.34 | |
|
DRAXIS Health Inc. (USA)
|
|
13.00% | 170.353 | 102.74 | 21.72 | 2.16 | 1.77 | 1.55 | |
|
Immunicon Corp.
|
|
13.00% | 9.169 | 0.00 | n/a | 0.64 | n/a | 1.06 | |
|
Kendle International Inc.
|
|
12.00% | 628.331 | 33.62 | 21.02 | 1.10 | 1.39 | n/a | |
|
etrials Worldwide, Inc.
|
|
10.00% | 25.417 | 0.00 | -5.12 | 1.13 | n/a | 1.30 | |
|
Sangamo Biosciences, Inc.
|
|
9.50% | 465.438 | 0.00 | -19.24 | 51.15 | 32.67 | 6.62 | |
|
Bioanalytical Systems, Inc.
|
|
7.30% | 29.486 | 83.29 | n/a | 0.64 | n/a | 1.81 | |
|
Bridgeline Software, Inc.
|
|
6.00% | 28.167 | 0.00 | n/a | 2.16 | n/a | 4.06 | |
|
Oracle Corporation
|
|
n/a | 97,595.171 | 20.42 | 15.51 | 4.86 | 4.51 | n/a | |
|
Bayer AG (ADR)
|
|
n/a | 54,726.881 | 7.55 | 14.14 | 1.19 | 1.27 | n/a | |
| Target | |||||||||
|
GPC Biotech AG (ADR)
|
|
66.00% | 123.561 | 0.00 | -1.04 | 3.95 | 3.84 | 1.63 | |
|
Celgene Corporation
|
|
n/a | 22,917.366 | 101.21 | 38.96 | 16.30 | 11.48 | 8.45 | |
|
salesforce.com, inc.
|
|
n/a | 6,759.538 | 368.29 | 174.97 | 9.03 | 6.62 | 16.14 | |
|
MethylGene Inc.
|
|
n/a | 87.304 | 0.00 | n/a | 6.00 | n/a | 1.75 | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
McKesson Corporation
|
|
20.00% | 16,575.105 | 17.63 | 17.42 | 0.17 | 0.16 | 5.60 | |
|
Cardinal Health, Inc.
|
|
13.00% | 19,851.610 | 12.83 | 14.65 | 0.22 | 0.21 | 15.33 | |
| Buyer | |||||||||
|
McKesson Corporation
|
|
20.00% | 16,575.105 | 17.63 | 17.42 | 0.17 | 0.16 | 5.60 | |
|
Cardinal Health, Inc.
|
|
13.00% | 19,851.610 | 12.83 | 14.65 | 0.22 | 0.21 | 15.33 | |
|
AmerisourceBergen Corp.
|
|
11.00% | 6,687.985 | 14.64 | 14.03 | 0.10 | 0.10 | n/a | |
|
sanofi-aventis (ADR)
|
|
n/a | 98,531.811 | 16.69 | 9.14 | 2.25 | 2.40 | n/a | |
|
Alcon, Inc.
|
|
n/a | 40,206.352 | 25.34 | 21.89 | 7.18 | 6.56 | 15.12 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,867.169 | 20.33 | 14.40 | 1.15 | 1.12 | 7.76 | |
|
United Therapeutics Corporation
|
|
n/a | 1,750.426 | 88.14 | 34.94 | 8.30 | 6.83 | 5.87 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 1,095.348 | 0.00 | -24.89 | 53.79 | 81.09 | 7.27 | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 915.697 | 12.90 | n/a | 0.44 | n/a | 1.77 | |
|
Sciele Pharma Inc.
|
|
n/a | 671.385 | 14.79 | 9.33 | 1.76 | 1.53 | 77.78 | |
|
MWI Veterinary Supply, Inc.
|
|
n/a | 414.377 | 24.42 | 21.09 | 0.55 | 0.50 | 3.23 | |
|
Insmed Incorporated
|
|
n/a | 90.209 | 0.00 | -4.44 | 11.98 | 10.20 | 7.85 | |
|
Insite Vision Inc.
|
|
n/a | 65.235 | 11.78 | -7.67 | 2.75 | n/a | 87.45 | |
|
Oscient Pharmaceuticals Corporation
|
|
n/a | 22.298 | 0.00 | -0.50 | 0.28 | 0.22 | n/a | |
| Target | |||||||||
|
US Oncology, Inc.
|
|
19.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cardinal Health, Inc.
|
|
11.00% | 19,851.610 | 12.83 | 14.65 | 0.22 | 0.21 | 15.33 | |
|
McKesson Corporation
|
|
9.00% | 16,575.105 | 17.63 | 17.42 | 0.17 | 0.16 | 5.60 | |
|
Government - United Kingdom
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Microsoft Corporation
|
|
n/a | 259,385.508 | 15.30 | 14.74 | 4.48 | 4.28 | 11.58 | |
|
International Business Machines Corp.
|
|
n/a | 157,730.669 | 15.14 | 13.66 | 1.60 | 1.50 | 13.06 | |
|
sanofi-aventis (ADR)
|
|
n/a | 98,531.811 | 16.69 | 9.14 | 2.25 | 2.40 | n/a | |
|
Bayer AG (ADR)
|
|
n/a | 54,726.881 | 7.55 | 14.14 | 1.19 | 1.27 | n/a | |
|
Gilead Sciences, Inc.
|
|
n/a | 45,235.974 | 28.00 | 24.90 | 10.69 | 8.79 | 13.07 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 43,309.011 | 20.00 | 12.88 | 2.24 | 2.02 | 10.23 | |
|
Novo Nordisk A/S (ADR)
|
|
n/a | 42,508.567 | 24.34 | 24.38 | 4.96 | 4.78 | 6.58 | |
|
Alcon, Inc.
|
|
n/a | 40,206.352 | 25.34 | 21.89 | 7.18 | 6.56 | 15.12 | |
|
Eisai Co., Ltd (ADR)
|
|
n/a | 9,661.528 | 13.56 | 13.89 | 1.46 | 1.40 | 2.29 | |
|
Sigma-Aldrich Corporation
|
|
n/a | 6,965.209 | 22.39 | 21.57 | 3.42 | 3.23 | 6.57 | |
|
Waters Corporation
|
|
n/a | 5,907.597 | 22.04 | 18.95 | 4.01 | 3.69 | 34.41 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,867.169 | 20.33 | 14.40 | 1.15 | 1.12 | 7.76 | |
|
Pharmion Corporation
|
|
n/a | 2,706.069 | 0.00 | -395.28 | 10.12 | 7.21 | 10.58 | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 144,347.120 | 17.73 | 9.11 | 2.98 | 3.03 | 6.24 | |
|
Celgene Corporation
|
|
n/a | 22,917.366 | 101.21 | 38.96 | 16.30 | 11.48 | 8.45 | |
|
Cardinal Health, Inc.
|
|
n/a | 19,851.610 | 12.83 | 14.65 | 0.22 | 0.21 | 15.33 | |
|
McKesson Corporation
|
|
n/a | 16,575.105 | 17.63 | 17.42 | 0.17 | 0.16 | 5.60 | |
|
GPC Biotech AG (ADR)
|
|
n/a | 123.561 | 0.00 | -1.04 | 3.95 | 3.84 | 1.63 | |
|
MethylGene Inc.
|
|
n/a | 87.304 | 0.00 | n/a | 6.00 | n/a | 1.75 | |
|
US Oncology, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
LEO Pharma A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Dainippon Sumitomo Pharma Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Nippon Shinyaku Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 48,418.0 | 267.3 | 48,685.3 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 48,418.0 | 267.3 | 48,685.3 |
|
Cost of Revenue
|
11,239.0 | 73.1 | 11,312.1 |
|
SG&A Expense
|
15,626.0 | 143.2 | 15,769.2 |
|
Depreciation & Amortization
|
3,128.0 | 9.9 | 3,137.9 |
|
Research & Development
|
8,089.0 | 102.4 | 8,191.4 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
-1,759.0 | 0.0 | -1,759.0 |
|
Unusual Expense (Income)
|
2,817.0 | 8.0 | 2,825.0 |
| Total Expenses | 39,140.0 | 336.5 | 39,476.5 |
|
Operating Income
|
9,278.0 | -69.2 | 9,208.8 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
0.0 | 10.2 | 10.2 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | 9,278.0 | -59.1 | 9,218.9 |
| Income Taxes | 1,023.0 | 4.8 | 1,027.8 |
| Income After Taxes | 8,255.0 | -63.9 | 8,191.1 |
| Minority Interest (IS) | -42.0 | 0.0 | -42.0 |
|
Net Income - Excl. Xord. Items
|
8,213.0 | -63.9 | 8,149.1 |
| Discontinued Operations | -69.0 | 0.0 | -69.0 |
|
Net Income - Incl. Xord. Items
|
8,144.0 | -63.9 | 8,080.1 |
| Preferred Dividends | -4.0 | 0.0 | -4.0 |
|
Income Avail. to Common
|
8,140.0 | -63.9 | 8,076.1 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
6,774.0 | 37.3 | 6,811.3 |
|
Basic EPS - Excl. Xord. Items
|
1.21 | n/a | 1.20 |
|
Basic EPS - Incl. Xord. Items
|
1.20 | n/a | 1.19 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 6,792.0 | 37.3 | 6,829.3 |
|
F.D. EPS - Excl. Xord. Items
|
1.21 | n/a | 1.19 |
|
F.D. EPS - Incl. Xord. Items
|
1.20 | n/a | 1.18 |
| Dividends Per Common Share | 1.16 | 0.00 | 1.16 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
3,406.0 | 178.9 | 3,584.9 |
|
ST Investments
|
22,686.0 | 69.7 | 22,755.7 |
|
Accounts Receivable
|
9,843.0 | 45.0 | 9,888.0 |
|
Inventory
|
5,302.0 | 12.8 | 5,314.8 |
|
Prepayments and Advances
|
5,498.0 | 2.8 | 5,500.8 |
|
Other Current Assets
|
114.0 | 13.6 | 127.6 |
|
Current Assets
|
46,849.0 | 322.8 | 47,171.8 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
15,734.0 | 11.4 | 15,745.4 |
| Goodwill & Intangibles | 41,880.0 | 103.1 | 41,983.1 |
| Long Term Investments | 4,856.0 | 0.0 | 4,856.0 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
5,949.0 | 6.0 | 5,955.0 |
| Total Assets | 115,268.0 | 443.3 | 115,711.3 |
| Liabilities | |||
| Accounts Payable | 2,270.0 | 14.3 | 2,284.3 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 1,974.0 | 66.3 | 2,040.3 |
|
ST Debt
|
4,801.0 | 0.0 | 4,801.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
1,024.0 | 0.0 | 1,024.0 |
| Other (Current) Liabilities | 11,766.0 | 0.0 | 11,766.0 |
|
Current Liab.
|
21,835.0 | 80.6 | 21,915.6 |
|
LT Debt
|
7,314.0 | 0.0 | 7,314.0 |
|
Total LT Debt
|
7,314.0 | 0.0 | 7,314.0 |
| Minority Interest (BS) | 114.0 | 0.0 | 114.0 |
| Deferred Taxes | 7,696.0 | 2.7 | 7,698.7 |
|
Other LT Liab.
|
13,299.0 | 1.1 | 13,300.1 |
|
Total Liabilities
|
50,258.0 | 84.4 | 50,342.4 |
| Shareholders Equity | |||
| Preferred Stock | 93.0 | 0.0 | 93.0 |
| Common Stock | 442.0 | 0.0 | 442.0 |
| Additional Paid in Capital | 69,913.0 | 631.7 | 70,544.7 |
| Retained Earnings | 49,660.0 | -290.7 | 49,369.3 |
| Treasure Stock | -56,847.0 | 0.0 | -56,847.0 |
| Other Equity | 2,299.0 | 17.9 | 2,316.9 |
| ESOP Debt Guarantee | -550.0 | 0.0 | -550.0 |
|
Total Equity
|
65,010.0 | 358.9 | 65,368.9 |
|
Total Liab. & Equity
|
115,268.0 | 443.3 | 115,711.3 |
|
Shares Outstanding
|
6,761.0 | 37.4 | 6,798.4 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 8,144.0 | -63.9 | 8,080.1 |
| CF Depreciation | 5,200.0 | 12.6 | 5,212.6 |
| CF Deferred Taxes | -2,788.0 | 0.0 | -2,788.0 |
| Other Non-Cash Items | 3,597.0 | 3.2 | 3,600.2 |
| Change in Working Capital | -800.0 | 24.5 | -775.5 |
| Total Cash From Operating Activities | 13,353.0 | -23.5 | 13,329.5 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,991.0 | -6.7 | -1,997.7 |
| Other Investing Cash Flows | 2,786.0 | 8.6 | 2,794.6 |
| Total Cash From Investing Activities | 795.0 | 1.8 | 796.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -7,975.0 | 0.0 | -7,975.0 |
| Purchase Or Sale of Stock | -9,535.0 | 138.0 | -9,397.0 |
| Purchase and Retirement of Debt | 4,900.0 | -0.9 | 4,899.1 |
| Other Financing Cash Flow | 0.0 | 0.4 | 0.4 |
| Total Cash From Financing Activities | -12,610.0 | 137.5 | -12,472.5 |
| Exchange Rate Effects | 41.0 | 3.2 | 44.2 |
| Net Change in Cash | 1,579.0 | 119.0 | 1,698.0 |
| Cash Taxes Paid | 5,617.0 | 3.0 | 5,620.0 |
| Cash Interest Paid | 643.0 | 0.2 | 643.2 |